04:15 AM EDT, 10/27/2025 (MT Newswires) -- Castle Biosciences ( CSTL ) said Sunday new data showed that its TissueCypher Barrett's Esophagus precision medicine test has demonstrated actionable risk insights for clinical management.

Medical insights generated by the test support earlier intervention for those at higher risk of progression to esophageal cancer and potentially reducing "unnecessary procedures" for those at lower risk, the company said.

Castle Biosciences ( CSTL ) said the research will be presented at the American College of Gastroenterology 2025 annual scientific meeting scheduled for Oct. 27-29, 2025 in Phoenix.